Biography

Andrew Nixon, PhD, MBA (Assistant Professor of Medicine) is Director of the Phase I Biomarker Laboratory at the Duke University Medical Center, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been selected to act as a Molecular Reference Laboratory for the oncology cooperative group, Cancer and Leukemia Group B (CALGB), a national clinical research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trials research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

<< back

Aushon BioSystems
43 Manning Rd
Billerica, MA 01821
1-877-287-4661
978-436-6400
info@aushon.com